ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS AND HIV-1 CO-INFECTED SUBJECTS

丙型肝炎病毒和 HIV-1 合并感染受试者的抗病毒治疗

• 批准号: 7375261
• 负责人: THOMAS C MERIGAN
• 金额: $ 6.32万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375261
• 关键词: ANTIVIRAL; MANAGEMENT; HEPATITIS; VIRUS; HIV

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase II, open-label, two-arm, long-term maintenance therapy study. This trial is designed to study whether long-term maintenance with pegylated-interferon alfa-2a (PEG-IFN) reduces the rate of liver fibrosis progression in subjects with HCV/HIV co-infection who have failed to achieve or maintain HCV loads below the limit of detection during treatment with PEG-IFN plus ribavirin. Both HCV treatment na¿ve and previously treated subjects will be enrolled.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这是一项II期、开放标签、双臂、长期维持治疗研究。这项试验旨在研究长期服用聚乙二醇化干扰素α-2a(聚乙二醇化干扰素-2a)是否能降低在聚乙二醇化干扰素加利巴韦林治疗期间未能达到或将丙型肝炎病毒载量维持在检测极限以下的丙型肝炎病毒/艾滋病毒混合感染者的肝纤维化进展速度。接受丙型肝炎病毒治疗的新受试者和先前接受治疗的受试者都将被纳入研究。